THE EFFECT OF SARS-COV-2 ON VESSELS AND THE INTERPLAY BETWEEN THE MEDICATIONS

Abstract

The World Health Organization (WHO) proclaimed In March 2020,  the Coronavirus Disease 2019 (COVID-2019) outbreak a global pandemic. Almost two years later, there have been over 600 million cases and more than 6.5 million fatalities globally [1]. Despite the fact that the specific mechanisms generating severe COVID-19 are unknown, it has been proposed that immunological dysregulation and high levels of pro-inflammatory cytokines may be important causes of tissue damage during the SARS-CoV-2 reaction. Statins, which are typically used to treat dyslipidemia, have received attention in this context due to their probable significance in the prognosis of COVID-19[2]. Several studies have emphasized their anti-inflammatory, immunomodulatory, antithrombotic, and antiviral capabilities, which may lead to better short- and long-term results in COVID-19 patients. Apparently, vascular lesions in COVID-19 are more substantial than viral cytotoxicity in cardiomyocytes. Of course, the cardiovascular consequences of COVID-19 are most dangerous for those with preexisting atherosclerosis, who already have chronic coronary/cerebral artery lesions and marginally diminished perfusion reserves of the myocardium and other essential organs.